Cisplatin, Vindesine, and Continuous Infusion of 5-Fluorouracil for Advanced Lung Cancer
Author Information
Author(s): T Nakano, H Ikegami, S Nakamura, I Kawase, H Nishikawa, S Yokota, M Yoshida, T Tachibana, T Igarashi, K Komuta, K Higashino
Primary Institution: Hyogo College of Medicine
Hypothesis
The study aims to evaluate the efficacy and toxicity of a combination treatment of cisplatin, vindesine, and continuously infused 5-fluorouracil in patients with advanced non-small-cell lung cancer.
Conclusion
The treatment regimen achieved a response rate similar to other active combination regimens for advanced non-small-cell lung cancer and was less toxic.
Supporting Evidence
- An overall response rate of 40.4% was observed in 47 evaluable patients.
- Responses were achieved in 61.1% of stage 3 patients and 27.6% of stage 4 patients.
- The median progression-free interval was 19.3 weeks.
- The median survival time was 41.6 weeks.
- Toxicity was well tolerated, with no gastrointestinal or renal toxicities exceeding WHO grade 2.
Takeaway
Doctors tested a new combination of three cancer drugs on patients with advanced lung cancer, and it worked well without causing too many side effects.
Methodology
Patients received cisplatin and vindesine on day 1, followed by a continuous infusion of 5-fluorouracil starting on day 8, repeated every 14 days for at least three cycles.
Limitations
The study had a small sample size and included only previously untreated patients.
Participant Demographics
Of the 47 evaluable patients, 83% were men, with a median age of 65 years; 53% had adenocarcinoma, 34% squamous cell carcinoma, and 13% large-cell carcinoma.
Statistical Information
Confidence Interval
95% confidence interval, 26.3-54.5%
Want to read the original?
Access the complete publication on the publisher's website